<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="12242"><DrugName>calcipotriol</DrugName><DrugNamesKey><Name id="42749785">Daivonex</Name><Name id="42749786">Dovonex</Name><Name id="43049733">Dovonex Scalp</Name><Name id="43034556">Psorcutan</Name><Name id="42749783">calcipotriene</Name><Name id="42749784">calcipotriol</Name><Name id="43034488">ドボネックス</Name></DrugNamesKey><DrugSynonyms><Name><Value>calcipotriene</Value><Types><Type>USAN</Type></Types></Name><Name><Value>calcipotriol</Value><Types><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>Daivonex</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Dovonex</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>calcipotriene, BMS</Value></Name><Name><Value>MC-903</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ドボネックス</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Psorcutan</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>BMS-181161</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Dovonex Scalp</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>112965-21-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17774">LEO Pharma A/S</CompanyOriginator><CompaniesPrimary><Company id="26065">Torii Pharmaceutical Co Ltd</Company><Company id="17774">LEO Pharma A/S</Company></CompaniesPrimary><CompaniesSecondary><Company id="1013295">Astellas Pharma Inc</Company><Company id="15065">Bristol-Myers Squibb Co</Company><Company id="15563">CSL Ltd</Company><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Company id="20334">Teikoku Seiyaku KK</Company><Company id="27724">Warner Chilcott plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="12242" type="Drug"><TargetEntity id="139088" type="siDrug">Calcipotriol</TargetEntity></SourceEntity><SourceEntity id="1013295" type="Company"><TargetEntity id="4295876965" type="organizationId">Astellas Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="15563" type="Company"><TargetEntity id="4295856855" type="organizationId">CSL Ltd</TargetEntity></SourceEntity><SourceEntity id="16227" type="Company"><TargetEntity id="4295876872" type="organizationId">Fujisawa Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="17774" type="Company"><TargetEntity id="4297354408" type="organizationId">Leo Pharma A/S</TargetEntity></SourceEntity><SourceEntity id="20334" type="Company"><TargetEntity id="4296410080" type="organizationId">Teikoku Seiyaku Co Ltd</TargetEntity></SourceEntity><SourceEntity id="26065" type="Company"><TargetEntity id="4295879868" type="organizationId">Torii Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="27724" type="Company"><TargetEntity id="4295894857" type="organizationId">Warner Chilcott PLC</TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"></TargetEntity><TargetEntity id="10037153" type="MEDDRA"></TargetEntity><TargetEntity id="D011565" type="MeSH"></TargetEntity><TargetEntity id="-1735788310" type="omicsDisease"></TargetEntity><TargetEntity id="490" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Psoriasis - UK - Jan-1991</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="281">Psoriasis</Indication></IndicationsPrimary><ActionsSecondary><Action id="15183">Topical antipsoriatic product</Action><Action id="2593">Vitamin D analog</Action></ActionsSecondary><Technologies><Technology id="612">Emulsion dermatological</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="611">Dermatological formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>D5A</Code><Name>TOPICAL ANTIPSORIASIS PRODUCTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-04-11T09:32:36.000Z</LastModificationDate><ChangeDateLast>2019-03-12T00:00:00.000Z</ChangeDateLast><AddedDate>1996-05-03T17:14:35.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Developed and launched by &lt;ulink linkID="17774" linkType="Company"&gt;LEO Pharma&lt;/ulink&gt; and licensees &lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb&lt;/ulink&gt; (BMS), &lt;ulink linkID="27724" linkType="Company"&gt;Galen Holdings&lt;/ulink&gt; (now &lt;ulink linkID="27724" linkType="Company"&gt;Warner Chilcott&lt;/ulink&gt;) and &lt;ulink linkID="20334" linkType="Company"&gt;Teikoku Seiyaku KK&lt;/ulink&gt;, and now marketed by LEO Pharma and  licensee   &lt;ulink linkID="17327" linkType="Company"&gt;Japan Tobacco&lt;/ulink&gt;, calcipotriol (calcipotriene; Dovonex; Daivonex) is a synthetic vitamin D3 analog [&lt;ulink linkID="302077" linkType="Reference"&gt;302077&lt;/ulink&gt;]. As a cream or ointment  (0.005%) formulation, calcipotriol alone or in combination with a moderate to very potent topical corticosteroid, cyclosporin A or &lt;ulink linkID="2417" linkType="Drug"&gt;acitretin&lt;/ulink&gt; is indicated for the treatment of plaque psoriasis. As a solution (0.005%) formulation, the product is indicated  for the topical treatment  of  scalp psoriasis [&lt;ulink linkID="1167897" linkType="Reference"&gt;1167897&lt;/ulink&gt;], [&lt;ulink linkID="1168520" linkType="Reference"&gt;1168520&lt;/ulink&gt;], [&lt;ulink linkID="1168524" linkType="Reference"&gt;1168524&lt;/ulink&gt;], [&lt;ulink linkID="1252059" linkType="Reference"&gt;1252059&lt;/ulink&gt;], [&lt;ulink linkID="1252151" linkType="Reference"&gt;1252151&lt;/ulink&gt;], [&lt;ulink linkID="1252429" linkType="Reference"&gt;1252429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;LEO Pharma launched calcipotriol in Denmark, Switzerland, the UK and Ireland for the treatment of psoriasis in 1991. In May 1993,  Daivonex ointment was approved and later in April 2012, it was withdrawn in Spain [&lt;ulink linkID="1356786" linkType="Reference"&gt;1356786&lt;/ulink&gt;]. The product was approved in  the US in December 1993, and by September 1998, the product had been launched in over 80 other countries, including European countries and  the US  [&lt;ulink linkID="299765" linkType="Reference"&gt;299765&lt;/ulink&gt;], [&lt;ulink linkID="302077" linkType="Reference"&gt;302077&lt;/ulink&gt;], [&lt;ulink linkID="552777" linkType="Reference"&gt;552777&lt;/ulink&gt;], [&lt;ulink linkID="1251724" linkType="Reference"&gt;1251724&lt;/ulink&gt;], [&lt;ulink linkID="1252464" linkType="Reference"&gt;1252464&lt;/ulink&gt;]. In June 2000, calcipotriol was launched in Japan [&lt;ulink linkID="487391" linkType="Reference"&gt;487391&lt;/ulink&gt;]. The ointment was withdrawn in the US by February 2008 [&lt;ulink linkID="1252120" linkType="Reference"&gt;1252120&lt;/ulink&gt;], [&lt;ulink linkID="2117896" linkType="Reference"&gt;2117896&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1995, &lt;ulink linkID="15065" linkType="Company"&gt;&lt;/ulink&gt;BMS filed an NDA for a solution formulation of calcipotriol for the treatment of scalp psoriasis [&lt;ulink linkID="206604" linkType="Reference"&gt;206604&lt;/ulink&gt;]; however, BMS subsequently divested the product  [&lt;ulink linkID="683751" linkType="Reference"&gt;683751&lt;/ulink&gt;]. In May 1997, the solution formulation of the product was approved  [&lt;ulink linkID="1356790" linkType="Reference"&gt;1356790&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The ointment formulation was discontinued in the UK in April 2007, and by January 2012, it had also been discontinued in the US [&lt;ulink linkID="1252120" linkType="Reference"&gt;1252120&lt;/ulink&gt;], [&lt;ulink linkID="1252155" linkType="Reference"&gt;1252155&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="27724" linkType="Company"&gt;&lt;/ulink&gt;LEO Pharma also markets &lt;ulink linkID="50974" linkType="Drug"&gt;Taclonex&lt;/ulink&gt;, a combination of calcipotriol and betamethasone dipropionate. LEO Pharma was also developing &lt;ulink linkID="50975" linkType="Drug"&gt;LEO-80190&lt;/ulink&gt;, a combination of calcipotriol and hydrocortisone, for the potential treatment of facial psoriasis [&lt;ulink linkID="910693" linkType="Reference"&gt;910693&lt;/ulink&gt;]. However, in March 2011, the drug was no longer listed on the company's pipeline [&lt;ulink linkID="1181899" linkType="Reference"&gt;1181899&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;Cream/ointment  formulations&lt;/subtitle&gt;The US patent for the ointment formulation expired in December 2007, and the US patent for the cream formulation expired in June 2015 (&lt;ulink linkID="IN2534480" linkType="Patent"&gt;US-05763426&lt;/ulink&gt;).&lt;/para&gt;&lt;para&gt;In March 2010, &lt;ulink linkID="29326" linkType="Company"&gt;Glenmark Pharmaceuticals&lt;/ulink&gt; was granted final FDA approval for its generic 0.005% calcipotriol ointment [&lt;ulink linkID="1086128" linkType="Reference"&gt;1086128&lt;/ulink&gt;]. In May 2015, Glenmark received tentative FDA approval for its generic 0.005% calcipotriol cream; the generic would be launched when final approval was received [&lt;ulink linkID="1656598" linkType="Reference"&gt;1656598&lt;/ulink&gt;]. By July 2016,  Glenmark's generic had been launched [&lt;ulink linkID="1784185" linkType="Reference"&gt;1784185&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2012,  Tolmar was granted FDA approval for its generic 0.005% calcipotriol topical cream [&lt;ulink linkID="1311933" linkType="Reference"&gt;1311933&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2012, &lt;ulink linkID="28696" linkType="Company"&gt;Sandoz&lt;/ulink&gt; launched its first-to-file and first-to-launch generic version of calcipotriene 0.005% cream in the US [&lt;ulink linkID="1313084" linkType="Reference"&gt;1313084&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solution   formulation&lt;/subtitle&gt;US patent coverage for the topical solution formulation expired in June 2015 [&lt;ulink linkID="809537" linkType="Reference"&gt;809537&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Prior to Warner Chilcott's acquisition of the product, LEO Pharma had received notices of Paragraph IV certifications in relation to the solution formulation of the product, which allowed generic competitors to launch in the US from January 2008 [&lt;ulink linkID="809537" linkType="Reference"&gt;809537&lt;/ulink&gt;]. FDA approval of &lt;ulink linkID="1002503" linkType="Company"&gt;Nycomed&lt;/ulink&gt;'s ANDA for calcipotriol solution 0.005% occurred in May 2008, with Nycomed's generic being the first to market [&lt;ulink linkID="1056259" linkType="Reference"&gt;1056259&lt;/ulink&gt;], [&lt;ulink linkID="1056315" linkType="Reference"&gt;1056315&lt;/ulink&gt;]. Also in May 2008, Warner Chilcott authorized &lt;ulink linkID="1008816" linkType="Company"&gt;Hi-Tech Pharmacal&lt;/ulink&gt; to launch a generic version of calcipotriol solution 0.005%; Hi-Tech was to begin shipping 'immediately' [&lt;ulink linkID="904235" linkType="Reference"&gt;904235&lt;/ulink&gt;]. By November 2009, LEO Pharma's own generic calcipotriol had been  FDA approved [&lt;ulink linkID="1066339" linkType="Reference"&gt;1066339&lt;/ulink&gt;]. That same month, the FDA approved an ANDA for &lt;ulink linkID="1050057" linkType="Company"&gt;Tolmar&lt;/ulink&gt;'s generic calcipotriol solution 0.005% [&lt;ulink linkID="1066339" linkType="Reference"&gt;1066339&lt;/ulink&gt;]. In December 2017, &lt;ulink linkID="21932" linkType="Company"&gt;Lupin&lt;/ulink&gt;'s generic calcipotriene topical solution 0.005%  was approved in the US [&lt;ulink linkID="1994068" linkType="Reference"&gt;1994068&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Cream/ointment  formulations&lt;/subtitle&gt;In December 1993, the ointment (0.005%) formulation was approved in the US and in  May 1996, the cream (0.005%)  formulation was approved [&lt;ulink linkID="1252459" linkType="Reference"&gt;1252459&lt;/ulink&gt;], [&lt;ulink linkID="1252461" linkType="Reference"&gt;1252461&lt;/ulink&gt;],  [&lt;ulink linkID="1252464" linkType="Reference"&gt;1252464&lt;/ulink&gt;]. By September 1998, the product had been launched in  the US [&lt;ulink linkID="299765" linkType="Reference"&gt;299765&lt;/ulink&gt;], [&lt;ulink linkID="302077" linkType="Reference"&gt;302077&lt;/ulink&gt;], [&lt;ulink linkID="552777" linkType="Reference"&gt;552777&lt;/ulink&gt;]. However, by February 2008, the ointment formulation had been withdrawn in the US [&lt;ulink linkID="1252120" linkType="Reference"&gt;1252120&lt;/ulink&gt;], [&lt;ulink linkID="2117896" linkType="Reference"&gt;2117896&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solution   formulation&lt;/subtitle&gt;In 1995, BMS filed an NDA for a solution formulation of calcipotriol for the treatment of scalp psoriasis [&lt;ulink linkID="206604" linkType="Reference"&gt;206604&lt;/ulink&gt;]; however, BMS subsequently divested the product  [&lt;ulink linkID="683751" linkType="Reference"&gt;683751&lt;/ulink&gt;]. In March 1997, the solution (0.005%) formulation was approved in the US [&lt;ulink linkID="1252459" linkType="Reference"&gt;1252459&lt;/ulink&gt;]. By September 1998, the product had been launched in  the US [&lt;ulink linkID="299765" linkType="Reference"&gt;299765&lt;/ulink&gt;], [&lt;ulink linkID="302077" linkType="Reference"&gt;302077&lt;/ulink&gt;], [&lt;ulink linkID="552777" linkType="Reference"&gt;552777&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Cream/ointment  formulations&lt;/subtitle&gt;In 1991,  calcipotriol was launched in Denmark, the UK and Ireland for the treatment of psoriasis [&lt;ulink linkID="1251724" linkType="Reference"&gt;1251724&lt;/ulink&gt;]. In May 1992, the product was approved in France [&lt;ulink linkID="1350842" linkType="Reference"&gt;1350842&lt;/ulink&gt;]. In May 1993,  Daivonex Ointment was approved and later in April 2012, it was withdrawn in Spain [&lt;ulink linkID="1356786" linkType="Reference"&gt;1356786&lt;/ulink&gt;].    In April 1995, the drug was approved in Lithuania [&lt;ulink linkID="1462801" linkType="Reference"&gt;1462801&lt;/ulink&gt;].  In August 1996, the drug was approved in Slovakia [&lt;ulink linkID="1466658" linkType="Reference"&gt;1466658&lt;/ulink&gt;] and was subsequently launched  [&lt;ulink linkID="1466334" linkType="Reference"&gt;1466334&lt;/ulink&gt;].  In April 1999, the drug was approved in Estonia [&lt;ulink linkID="1462068" linkType="Reference"&gt;1462068&lt;/ulink&gt;]. In September 2005, the drug was approved in Malta [&lt;ulink linkID="1453614" linkType="Reference"&gt;1453614&lt;/ulink&gt;]. However, in  April 2007, the ointment formulation was discontinued in the UK [&lt;ulink linkID="1252155" linkType="Reference"&gt;1252155&lt;/ulink&gt;]. By July 2015, the product had been launched in France [&lt;ulink linkID="2127474" linkType="Reference"&gt;2127474&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1991, calcipotriol was launched in Switzerland [&lt;ulink linkID="1251724" linkType="Reference"&gt;1251724&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solution  formulation&lt;/subtitle&gt;By June 1994, the calcipotriol solution formulation had been approved in the UK for the treatment of scalp psoriasis [&lt;ulink linkID="1168524" linkType="Reference"&gt;1168524&lt;/ulink&gt;]. In May 1997, the solution formulation of the product was approved and later in January 2013, it was withdrawn in Spain [&lt;ulink linkID="1356790" linkType="Reference"&gt;1356790&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;&lt;subtitle&gt;Cream/ointment  formulations&lt;/subtitle&gt;In January 2000, calcipotriol was approved in Japan [&lt;ulink linkID="1565719" linkType="Reference"&gt;1565719&lt;/ulink&gt;]. In June 2000, calcipotriol was launched in Japan [&lt;ulink linkID="487391" linkType="Reference"&gt;487391&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Cream/ointment  formulations&lt;/subtitle&gt;By September 1998,  calcipotriol had been launched in  over 80 other countries [&lt;ulink linkID="299765" linkType="Reference"&gt;299765&lt;/ulink&gt;], [&lt;ulink linkID="302077" linkType="Reference"&gt;302077&lt;/ulink&gt;], [&lt;ulink linkID="552777" linkType="Reference"&gt;552777&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;&lt;subtitle&gt;Cream/ointment  formulations&lt;/subtitle&gt;In October 1992 and February 1995, the ointment and cream formulations of the product, respectively, were approved in Canada [&lt;ulink linkID="1256702" linkType="Reference"&gt;1256702&lt;/ulink&gt;]. By December 1992 and May 1995, the ointment and cream formulations of the product, respectively, had been launched in Canada [&lt;ulink linkID="1252303" linkType="Reference"&gt;1252303&lt;/ulink&gt;], [&lt;ulink linkID="1252304" linkType="Reference"&gt;1252304&lt;/ulink&gt;], [&lt;ulink linkID="1252305" linkType="Reference"&gt;1252305&lt;/ulink&gt;], [&lt;ulink linkID="1256702" linkType="Reference"&gt;1256702&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solution  formulation&lt;/subtitle&gt;In November 1995, the solution formulation of the product was approved in Canada, and in April 1996, the product was launched [&lt;ulink linkID="1252305" linkType="Reference"&gt;1252305&lt;/ulink&gt;], [&lt;ulink linkID="1256702" linkType="Reference"&gt;1256702&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;&lt;subtitle&gt;Cream/ointment  formulations&lt;/subtitle&gt;In September 1996, the product was approved in Australia [&lt;ulink linkID="1251670" linkType="Reference"&gt;1251670&lt;/ulink&gt;]; by June 1999, the product had been launched in Australia by CSL [&lt;ulink linkID="343576" linkType="Reference"&gt;343576&lt;/ulink&gt;]. By August 2012, however, CSL no longer listed Daivonex under its marketed products listings,  so it was presumed that CSL were no longer marketing the product in this territory, and that marketing rights had defaulted to Leo Pharma [&lt;ulink linkID="1332036" linkType="Reference"&gt;1332036&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In April 2005,  a randomized, double-blind, placebo-controlled, phase IV safety and efficacy  trial (&lt;ulink linkID="36629" linkType="Protocol"&gt;NCT00216892&lt;/ulink&gt;; MCB 0402 INT) in patients (n = 1032) with psoriasis was initiated. Different treatment regimens of calcipotriol cream, and &lt;ulink linkID="50974" linkType="Drug"&gt;calcipotriol + betamethasone dipropionate&lt;/ulink&gt; ointment, following treatment with combination ointment, were assessed. The study was completed in December 2005 [&lt;ulink linkID="1103397" linkType="Reference"&gt;1103397&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Cream/ointment  formulations&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In  September 2008, a randomized, active-controlled Canadian phase II study (&lt;ulink linkID="36657" linkType="Protocol"&gt;NCT00764751&lt;/ulink&gt;) was initiated. The study compared the efficacy and safety of  &lt;ulink linkID="56719" linkType="Drug"&gt;LEO-19123&lt;/ulink&gt; cream      with calcipotriol cream versus LEO-19123 cream vehicle alone in patients  (n = 51) with psoriasis vulgaris. The study was completed in January 2009 [&lt;ulink linkID="1168342" linkType="Reference"&gt;1168342&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In November 2011, a single-blind, active-controlled, phase I study (&lt;ulink linkID="82187" linkType="Protocol"&gt;NCT01466478&lt;/ulink&gt;; PLQ-007; 2011-003058-25) was initiated in patients with psoriasis vulgaris (expected n = 24) in France, to assess the safety and efficacy of &lt;ulink linkID="59534" linkType="Drug"&gt;LEO-29102&lt;/ulink&gt; in combination with calcipotriol, compared with LEO-29102, calcipotriol or &lt;ulink linkID="44281" linkType="Drug"&gt;betamethasone&lt;/ulink&gt; alone. At that time, the study was expected to complete in January 2012 [&lt;ulink linkID="1242285" linkType="Reference"&gt;1242285&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2010, a randomized, single-blind, single-group assignment, phase I trial (&lt;ulink linkID="83741" linkType="Protocol"&gt;NCT01105286&lt;/ulink&gt;; PLQ-005; 2009-017393-20) evaluating six formulations of calcipotriol ointment and two topical vitamin D analogs began in healthy volunteers (expected n = 24) in France. The primary endpoint was total clinical score of clinical symptoms at week 4. The trial completed in June 2010 [&lt;ulink linkID="1252030" linkType="Reference"&gt;1252030&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, a randomized, single-blind, single-group assignment, phase I trial (&lt;ulink linkID="67204" linkType="Protocol"&gt;NCT01105234&lt;/ulink&gt;; MCO 0901 FR; 2009-017394-38) evaluating six formulations of calcipotriol ointment and two topical vitamin D analogs began in healthy volunteers  (expected n = 24) in France. The primary endpoint was clinical scoring of the skin reaction at day 10. The trial completed in May 2010 [&lt;ulink linkID="1252029" linkType="Reference"&gt;1252029&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous studies&lt;/subtitle&gt;By October 2007, results from an 8-week, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study (DE127-009) had been reported. Patients with plaque psoriasis received calcipotriol ointment (n = 99) or placebo (n = 99) ointment (both qd). Significant reductions in erythema, scaling, plaque elevation and overall disease severity were observed from week 4 to week 8. A favorable effect on physician's global assessment (PGA) score was observed from week 1 to week 8 of treatment [&lt;ulink linkID="1252429" linkType="Reference"&gt;1252429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2007, results from an 8-week, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study (DE127-007) had been reported. Patients with plaque psoriasis received calcipotriol ointment (n = 118) or placebo (n = 117) ointment (both qd). Significant reductions in mean scores for erythema, scaling, plaque elevation and overall disease severity were observed following calcipotriol treatment compared with placebo at weeks 4 to 8. A favorable effect on PGA score was observed from week 1 to week 8 of treatment [&lt;ulink linkID="1252429" linkType="Reference"&gt;1252429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2007, results from a multicenter, randomized, double-blind, vehicle-controlled, parallel-group study (DE127-003) had been reported. Patients with stable plaque psoriasis received calcipotriol ointment (n = 139) or placebo (n = 138) ointment (both bid). Significant reductions in severity scores for all symptoms, overall severity score and PGA score were observed following calcipotriol treatment compared with placebo at weeks 1 to 8. At total of 70% of calcipotriol-treated patients were clear or demonstrated improvement at week 8, compared with 19% of patients receiving placebo [&lt;ulink linkID="1252429" linkType="Reference"&gt;1252429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2007, results from a multicenter, randomized, double-blind, vehicle-controlled, parallel-group study (DE127-001) had been reported. Patients with stable plaque psoriasis received calcipotriol ointment (n = 167) or placebo (n = 168) ointment (both bid). Significant reductions in severity scores for all symptoms, overall severity score and physician's global assessment were observed following calcipotriol treatment compared with placebo at weeks 1 to 8. At total of 70% of calcipotriol-treated patients were clear or demonstrated improvement at week 8, compared with 22% of patients receiving placebo [&lt;ulink linkID="1252429" linkType="Reference"&gt;1252429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2007, results from a multicenter, randomized, double-blind, right-left, comparative study (MC 9307 INT) had been reported. Patients (n = 77) with psoriasis vulgaris received calcipotriol ointment bid plus UVB therapy on one side of the body and placebo ointment bid plus UVB therapy on the other side of the body. The combination treatment resulted in favorable Psoriasis Area and Severity Index (PASI) reduction and overall assessment of response at week 2; at the end of treatment, PASI and investigator and patient assessment of overall response were similar for both treatment groups [&lt;ulink linkID="1252429" linkType="Reference"&gt;1252429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2007, results from a multicenter, randomized, double-blind, comparative, parallel-group study (MC 590) had been reported. Patients with extensive psoriasis in whom PUVA therapy was indicated received calcipotriol ointment bid for 2 weeks followed by placebo ointment bid plus PUVA therapy for 10 weeks (n= 54), or placebo ointment bid for 2 weeks followed by calcipotriol ointment bid plus PUVA therapy for 10 weeks (n = 53). Significant reductions in PASI were observed for the combination treatment of calcipotriol plus PUVA  compared with placebo plus PUVA treatment (91 versus 76%, respectively). Patients receiving the calcipotriol plus PUVA  combination treatment required significantly reduced UVA dose (37%), fewer doses (26%) and a shorter treatment period (24%). The calcipotriol plus PUVA  combination treatment resulted in favorable patient assessment of overall response [&lt;ulink linkID="1252429" linkType="Reference"&gt;1252429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2007, results from a multicenter, randomized, single-blind, comparative, parallel-group study (MCC 9504 CAN) had been reported. Patients with extensive plaque psoriasis vulgaris received calcipotriol cream bid plus UVB phototherapy biw (n = 80) or placebo cream bid plus UVB phototherapy tiw (n = 80). Calcipotriol plus UVB biw was as effective as placebo plus UVB tiw at reducing PASI and in investigator and patient assessments of overall response . Patients receiving calcipotriol experienced an 80% reduction in PASI or psoriasis clearance and received significantly less UVB treatments and a lower cumulative dose of UVB [&lt;ulink linkID="1252429" linkType="Reference"&gt;1252429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2007, results from a multicenter, randomized, double-blind, right-left, comparative study (MC 390) had been reported. Patients (n = 101) with moderate-to-severe plaque psoriasis vulgaris received calcipotriol ointment bid plus UVB therapy on one side of the body and  calcipotriol ointment bid on the other side of the body. The combination treatment resulted in favorable PASI reduction and investigators overall assessment at all time points [&lt;ulink linkID="1252429" linkType="Reference"&gt;1252429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2007, results from a multicenter, randomized, double-blind, comparative, parallel-group study (DE127-019) had been reported. Patients with stable plaque psoriasis received calcipotriol ointment (n = 42, bid), &lt;ulink linkID="6292" linkType="Drug"&gt;ulobetasol&lt;/ulink&gt; ointment (n = 42, bid) or calcipotriol plus ulobetasol ointment (n = 42, qd). The combination treatment resulted in a significant reduction in plaque elevation and overall severity at day 14, and in PGA score at day 7 and 14 [&lt;ulink linkID="1252429" linkType="Reference"&gt;1252429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2007, results from a multicenter, randomized, double-blind, comparative, parallel-group study (MC 9306 INT) had been reported. Patients with severe or extensive psoriasis vulgaris unresponsive to topical treatment alone received calcipotriol ointment bid plus &lt;ulink linkID="2417" linkType="Drug"&gt;acitretin&lt;/ulink&gt; (n = 76) or placebo ointment bid plus acitretin (n = 59). The combination treatment resulted in favorable PASI reduction and investigators overall assessment. A total of 67% of patients receiving calcipotriol plus acitretin combination treatment achieved clearance or marked improvement compared with 41% of patients receiving acitretin alone. The cumulative dose of acitretin required to achieve clearance was significantly reduced by 20% in patients receiving the calcipotriol plus acitretin combination treatment [&lt;ulink linkID="1252429" linkType="Reference"&gt;1252429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2007, results from a multicenter, randomized, double-blind, comparative, parallel-group study (MC 9101 F) had been reported. Patients with severe psoriatic lesions received calcipotriol (n = 35) or placebo ointment (n = 34, both bid) plus low-dose oral cyclosporine. A total of 50% of patients receiving the calcipotriol plus cyclosporine combination achieved clearance or PASI reduction of &amp;gt; 90%, compared with 12% of patients receiving cyclosporin alone. At the end of 6 weeks of treatment, PASI was reduced by 80% for the combination treatment versus 58% for cyclosporine alone. Favorable effects on investigator and patient overall assessments were observed for the calcipotriol plus cyclosporine combination  [&lt;ulink linkID="1252429" linkType="Reference"&gt;1252429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2007, results from a multicenter, randomized, double-blind, comparative, parallel-group study (MC 9302 INT) had been reported. Patients with psoriasis vulgaris received calcipotriol plus &lt;ulink linkID="52281" linkType="Drug"&gt;clobetasone 17-butyrate&lt;/ulink&gt; 0.05% cream (n = 175, qd), calcipotriol plus &lt;ulink linkID="44281" linkType="Drug"&gt;betamethasone 17-valerate&lt;/ulink&gt; 0.1% cream (n = 176, qd), calcipotriol cream (n = 174, bid) or calcipotriol plus placebo cream (n = 174, qd). Once-daily calcipotriol resulted in marked improvement or clearance in 28% of patients and 41% of patients demonstrated a decrease in PASI; twice-daily administration of calcipotriol had greater efficacy compared with once-daily administration. Calcipotriol plus betamethasone treatment resulted in a significantly greater decrease in PASI compared with all other treatment groups [&lt;ulink linkID="1252429" linkType="Reference"&gt;1252429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solution formulation&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In September 2005, a randomized, single-blind, parallel-assignment, phase III trial (&lt;ulink linkID="36631" linkType="Protocol"&gt;NCT00243464&lt;/ulink&gt;; MBL 0503 INT) evaluating calcipotriol plus betamethasone dipropionate gel versus calcipotriol scalp solution began in patients (expected n = 300) in Europe and Canada with scalp psoriasis. The primary endpoint was overall disease severity at week 8. By August 2007, the trial had completed [&lt;ulink linkID="1252026" linkType="Reference"&gt;1252026&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By January 2006, preclinical results demonstrated calcipotriene  applied topically to mice for up to 2 years at dosages of 3, 10 and 30 microg/kg/day did not  result in  significant changes in tumor incidence  when compared with control [&lt;ulink linkID="1167897" linkType="Reference"&gt;1167897&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2006, preclinical results in albino hairless mice  exposed to  ultraviolet radiation (UVR) and topically applied calcipotriol were reported. A reduction in the time required for UVR to induce the formation of skin tumors was observed (statistically significant in males only). This suggested that calcipotriene may enhance the effect of UVR to induce skin tumors [&lt;ulink linkID="1167897" linkType="Reference"&gt;1167897&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2006, preclinical results in oral teratogenicity studies  performed in rabbits revealed an increase in rabbit maternal and fetal toxicity was  at 12 microg/kg/day. Rabbits administered 36 microg/kg/day demonstrated fetuses with a significant increase in the incidences of pubic bones, forelimb phalanges, and incomplete bone ossification. The maternal and fetal calculated no-effect exposure of 17.6 microg/m2/day were considered approximately equal to the expected human systemic exposure level of 18.5 microg/m2/day from dermal application [&lt;ulink linkID="1167897" linkType="Reference"&gt;1167897&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2006, preclinical results in rats demonstrated oral doses of 54 microg/kg/day resulted in a significantly higher incidence of skeletal abnormalities. The enlarged fontanelles seen were attributed to calcipotriene's effect upon calcium metabolism. The maternal and fetal calculated no-effect exposure of 43.2 microg/m2/day  were considered approximately equal to the expected human systemic exposure level of 18.5 microg/m2/day from dermal application [&lt;ulink linkID="1167897" linkType="Reference"&gt;1167897&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In May 2015, the EMA's Pediatric Committee (PDCO)  adopted a positive opinion on a  paediatric investigation plan (PIP) for the treatment of   psoriasis  [&lt;ulink linkID="1667442" linkType="Reference"&gt;1667442&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17774">LEO Pharma A/S</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1991-12-31T00:00:00.000Z</StatusDate><Source id="552777" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17774">LEO Pharma A/S</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1991-01-01T00:00:00.000Z</StatusDate><Source id="1168520" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17774">LEO Pharma A/S</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-10-26T00:00:00.000Z</StatusDate><Source id="302077" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17774">LEO Pharma A/S</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-07-20T00:00:00.000Z</StatusDate><Source id="2127474" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17774">LEO Pharma A/S</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-10-01T00:00:00.000Z</StatusDate><Source id="299765" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17774">LEO Pharma A/S</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1991-12-31T00:00:00.000Z</StatusDate><Source id="1251724" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17774">LEO Pharma A/S</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-08-22T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17774">LEO Pharma A/S</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-09-23T00:00:00.000Z</StatusDate><Source id="1044265" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17774">LEO Pharma A/S</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1992-12-31T00:00:00.000Z</StatusDate><Source id="1252304" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26065">Torii Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-10-31T00:00:00.000Z</StatusDate><Source id="807926" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17774">LEO Pharma A/S</Company><Country id="LT">Lithuania</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1995-04-05T00:00:00.000Z</StatusDate><Source id="1462801" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17774">LEO Pharma A/S</Company><Country id="MT">Malta</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-09-07T00:00:00.000Z</StatusDate><Source id="1453614" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17774">LEO Pharma A/S</Company><Country id="EE">Estonia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-04-09T00:00:00.000Z</StatusDate><Source id="1462068" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17774">LEO Pharma A/S</Company><Country id="ES">Spain</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-04-25T00:00:00.000Z</StatusDate><Source id="1356786" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-01-01T00:00:00.000Z</StatusDate><Source id="895643" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20334">Teikoku Seiyaku KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-06-30T00:00:00.000Z</StatusDate><Source id="1190799" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27724">Warner Chilcott plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-09-23T00:00:00.000Z</StatusDate><Source id="1044265" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-01-26T00:00:00.000Z</StatusDate><Source id="683751" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17774">LEO Pharma A/S</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-09-23T00:00:00.000Z</StatusDate><Source id="1251670" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-06-30T00:00:00.000Z</StatusDate><Source id="487391" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1013295">Astellas Pharma Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-04-01T00:00:00.000Z</StatusDate><Source id="592748" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17774">LEO Pharma A/S</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1993-12-29T00:00:00.000Z</StatusDate><Source id="1252464" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20334">Teikoku Seiyaku KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-06-30T00:00:00.000Z</StatusDate><Source id="487391" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17774">LEO Pharma A/S</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1992-10-31T00:00:00.000Z</StatusDate><Source id="1256702" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17774">LEO Pharma A/S</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1993-05-01T00:00:00.000Z</StatusDate><Source id="1356786" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20334">Teikoku Seiyaku KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-01-31T00:00:00.000Z</StatusDate><Source id="1565719" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15563">CSL Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-06-30T00:00:00.000Z</StatusDate><Source id="343576" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17774">LEO Pharma A/S</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1992-05-25T00:00:00.000Z</StatusDate><Source id="1350842" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-05-03T17:14:36.000Z</StatusDate><Source id="206604" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20334">Teikoku Seiyaku KK</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-10-01T00:00:00.000Z</StatusDate><Source id="299765" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-10-01T00:00:00.000Z</StatusDate><Source id="299765" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-11-01T00:00:00.000Z</StatusDate><Source id="223842" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27724">Warner Chilcott plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-01-15T00:00:00.000Z</StatusDate><Source id="683751" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1088700">Allergan plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="15563">CSL Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17327">Japan Tobacco Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17774">LEO Pharma A/S</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>3</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="20334">Teikoku Seiyaku KK</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>2</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>3</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>3</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>2</CountActive><CountInactive>2</CountInactive><CountTotal>4</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@H](/C=C/[C@H](C1CC1)O)[C@H]2CC[C@@H]\3[C@@]2(CCC/C3=C\C=C/4\C[C@H](C[C@@H](C4=C)O)O)C</Smiles></StructureSmiles><Deals><Deal id="108307" title="Warner Chilcott to acquire US rights to LEO Pharma's dermatology portfolio"></Deal><Deal id="109496" title="Warner-Chilcott and Bristol-Myers Squibb to copromote calcipotriene in the US for psoriasis"></Deal><Deal id="119005" title="BMS to develop LEO Pharma's calcipotriene in the US and Mexico"></Deal><Deal id="119008" title="Teikoku Seiyaku KK to develop LEO Pharma's calcipotriene in Japan   "></Deal><Deal id="119010" title="Fujisawa Pharmaceutical and Teikoku Seiyaku to comarket calcipotriene in Japan"></Deal><Deal id="119012" title="Teikoku and Torii Pharmaceutical to comarket calcipotriene in Japan"></Deal><Deal id="119014" title="CSL to market LEO Pharma's calcipotriene in Australia"></Deal></Deals><PatentFamilies><PatentFamily id="1037483" number="WO-2011154004" title="A pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid"></PatentFamily><PatentFamily id="1058664" number="US-05886038" title="Compositions and method for treatment of psoriasis."></PatentFamily><PatentFamily id="1091379" number="WO-00064450" title="Pharmaceutical composition."></PatentFamily><PatentFamily id="109413" number="WO-2008065514" title="Pharmaceutical compositions containing anhydrous calcipotriene"></PatentFamily><PatentFamily id="123626" number="WO-00156982" title="Vitamin D-derivatives and their use in treating osteoporosis and related bone disorders"></PatentFamily><PatentFamily id="1255688" number="WO-2011076207" title="Cutaneous composition comprising vitamin D analogue and a mixture of solvent and surfactants"></PatentFamily><PatentFamily id="1366922" number="WO-2007082533" title="Isomerisation of pharmaceutical intermediates"></PatentFamily><PatentFamily id="1367415" number="WO-2008012645" title="Methods for generating mammalian models of atopic diseases, and screening for their treatment"></PatentFamily><PatentFamily id="1396139" number="WO-2005110979" title="Process and intermediates to prepare the sulfonyl derivatives of cholecalciferol"></PatentFamily><PatentFamily id="1442291" number="WO-2008110815" title="Polyaphron topical composition with vitamin D and corticosteroid"></PatentFamily><PatentFamily id="1547219" number="WO-2006071129" title="Process for preparation of a pharmaceutical grade calcipotriol anhydrous"></PatentFamily><PatentFamily id="158838" number="WO-08700834" title="Novel vitamin D analogues."></PatentFamily><PatentFamily id="1589201" number="WO-2007082542" title="Compositions comprising oxaprozin and a vitamin d3 analogue and their use for the manufacture of a medicament for the treatment of psoriasis"></PatentFamily><PatentFamily id="1710250" number="WO-2012128653" title="Use of anastrozole and vitamin D analog in the combined therapy of breast cancer"></PatentFamily><PatentFamily id="178682" number="WO-2004046097" title="A crystallization method for purification of calcipotriene"></PatentFamily><PatentFamily id="1900658" number="WO-2005095336" title="Novel method for the preparation of intermediates useful for the synthesis of vitamin D analogues"></PatentFamily><PatentFamily id="2032724" number="US-20070088007" title="Method for preparing analogue of vitamin D"></PatentFamily><PatentFamily id="20866" number="WO-09415912" title="New crystalline form of a vitamin D analogue."></PatentFamily><PatentFamily id="2095153" number="US-07507865" title="Method for obtaining calcipotriol hydrate"></PatentFamily><PatentFamily id="2176780" number="WO-2004016257" title="A composition comprising phytospingosine derivatives for apoptosis induction"></PatentFamily><PatentFamily id="2177993" number="WO-2005087719" title="Stereoselective synthesis of vitamin D analogues"></PatentFamily><PatentFamily id="2214103" number="CN-01948283" title="Method for preparing vitamin D derivative"></PatentFamily><PatentFamily id="225646" number="WO-2012113803" title="A cyclic peptide and conjugate thereof for binding to keratinocytes"></PatentFamily><PatentFamily id="2290105" number="WO-2006024296" title="Epimerisation of allylic alcohols"></PatentFamily><PatentFamily id="2297522" number="WO-2010143986" title="Combined therapy of colorectal carcinoma"></PatentFamily><PatentFamily id="2329642" number="WO-2008027532" title="Stable pharmacologically active compositions including vitamin D-containing and corticosteroid compounds with low pH compatibility"></PatentFamily><PatentFamily id="2394734" number="WO-2012150892" title="Treatment of psoriasis"></PatentFamily><PatentFamily id="2510003" number="CN-102988987" title="One for a skin over drug composition for treating a proliferative disease and preparation thereof"></PatentFamily><PatentFamily id="2664372" number="WO-2014006201" title="A topical composition comprising a film-forming polymer for delivering an active ingredient to skin"></PatentFamily><PatentFamily id="272861" number="US-20060034779" title="Foamable compositions containing vitamin d3 analogues, processes for preparing same and methods of treatment utilizng same"></PatentFamily><PatentFamily id="2746931" number="CN-103705941" title="Calcipotriol b-cyclodextrin inclusion compound and preparation method thereof"></PatentFamily><PatentFamily id="2752352" number="WO-2014083099" title="A method of inhibiting the expression of IL-22 in activated T-cells"></PatentFamily><PatentFamily id="2813884" number="WO-2014177123" title="Acne medication and method for producing same"></PatentFamily><PatentFamily id="2822939" number="WO-2014176394" title="Vitamin D receptor/smad genomic circuit gates fibrotic response"></PatentFamily><PatentFamily id="2839515" number="WO-2014197680" title="Vitamin D receptor agonists to treat diseases involving CXCL12 activity"></PatentFamily><PatentFamily id="2871704" number="CN-104138352" title="Calcipotriol non hydrogel"></PatentFamily><PatentFamily id="2920957" number="CN-104478921" title="Intermediate calcipotriol mb and the impurity separation measuring method"></PatentFamily><PatentFamily id="293566" number="WO-2011076206" title="Pharmaceutical composition comprising vitamin D analogue and cosolvent-surfactant mixture"></PatentFamily><PatentFamily id="2938505" number="WO-2015072909" title="Sprayable topical carrier and composition comprising phosphatidylcholine"></PatentFamily><PatentFamily id="2966492" number="RU-02536274" title="Method of treating warts"></PatentFamily><PatentFamily id="3189806" number="CN-105534996" title="A pharmaceutical composition for treating psoriasis"></PatentFamily><PatentFamily id="3219394" number="CN-105624215" title="Calcipotriol synthesis method"></PatentFamily><PatentFamily id="3233897" number="CN-105717206" title="Method for separating and measuring calcipotriol intermediate f and its impurity"></PatentFamily><PatentFamily id="3234804" number="CN-105708842" title="An external medicine composition"></PatentFamily><PatentFamily id="3258994" number="CN-105777665" title="Cacipotriol of intermediate compound and preparation method thereof"></PatentFamily><PatentFamily id="3279029" number="CN-105753758" title="Preparation method of calcipotriol"></PatentFamily><PatentFamily id="3285278" number="WO-2017207818" title="Combination therapy comprising a polyunsaturated ketone and a secosteroid"></PatentFamily><PatentFamily id="3285279" number="WO-2017207821" title="Combination therapy comprising a polyunsaturated ketone and a corticosteroid"></PatentFamily><PatentFamily id="3372410" number="WO-2016149382" title="Compositions and methods for suppressing or reducing systemic immune response in a subject"></PatentFamily><PatentFamily id="3449861" number="EP-03095440" title="Antigen-specific immunotherapy using tolerizing liposomes"></PatentFamily><PatentFamily id="3478567" number="WO-2016198472" title="Topical delivery system"></PatentFamily><PatentFamily id="3515598" number="CN-106265511" title="A calcipotriol performance of betamethasone self-microemulsion"></PatentFamily><PatentFamily id="3515617" number="CN-106265485" title="Stability improvement of calcipotriol composition"></PatentFamily><PatentFamily id="3540349" number="CN-106344589" title="A stability improvement of calcipotriol betamethasone composition"></PatentFamily><PatentFamily id="3544271" number="CN-106431952" title="A medicine intermediate [epsilon]-(3, 4, 5-trimethoxy benzoylamino) - acetic acid synthesis method"></PatentFamily><PatentFamily id="3706885" number="CN-106908524" title="Calcipotriol intermediate l and separating and measuring method for gene toxicity of potential impurities"></PatentFamily><PatentFamily id="3707221" number="CN-106905358" title="Method for preparing vitamin D3 analog intermediate"></PatentFamily><PatentFamily id="3725603" number="ES-02620905" title="Procedimiento para reducir cetonas derivadas de vitamina d en continuo y procedimiento de fabricación de calcipotriol y uso correspondiente"></PatentFamily><PatentFamily id="3805760" number="CN-107157917" title="Preparation method of ointment for treating psoriasis"></PatentFamily><PatentFamily id="3853439" number="CN-104666312" title="Formulations containing calcipotriol and betamethasone dipropionate"></PatentFamily><PatentFamily id="3901294" number="CN-107473941" title="Cyclopropyl substituted allyl and asymmetric synthesis method thereof"></PatentFamily><PatentFamily id="4045175" number="WO-2018083227" title="Combination therapy comprising a thiazole and a secosteroid to treat skin conditions"></PatentFamily><PatentFamily id="4101080" number="CN-108147954" title="Preparation method of cacipotriol intermediate"></PatentFamily><PatentFamily id="4242683" number="CN-108653195" title="Transdermal or transmucosal administration preparation"></PatentFamily><PatentFamily id="4278820" number="CN-108815174" title="Improved fat composition and preparation method thereof"></PatentFamily><PatentFamily id="4309773" number="CN-108904445" title="Calcipotriol nanometre suspension"></PatentFamily><PatentFamily id="431212" number="WO-03087048" title="Preparation of 24 alkyl analogs of cholecalciferol and non-racemic compounds"></PatentFamily><PatentFamily id="4372861" number="CN-109180547" title="Medicine for vitamin D synthesis method and application for treating type 2 diabetes"></PatentFamily><PatentFamily id="4437469" number="CN-109453180" title="New application for bio-active vitamin D derivatives or analogues"></PatentFamily><PatentFamily id="446241" number="WO-2012049677" title="Compositions for treating psoriasis of the scalp"></PatentFamily><PatentFamily id="4474886" number="WO-2019072353" title="Topical pharmaceutical preparation of betamethasone, calcipotriol and rose oil for treatment of psoriasis"></PatentFamily><PatentFamily id="4496744" number="WO-2019094500" title="Compositions and methods for the treatment of skin lesions"></PatentFamily><PatentFamily id="4562869" number="WO-2019126744" title="Compositions and methods for treating neoplasia"></PatentFamily><PatentFamily id="50530" number="WO-2009008754" title="Process for the preparation of calcipotriol"></PatentFamily><PatentFamily id="515221" number="WO-2011076209" title="Pharmaceutical composition comprising solvent mixture and a vitamin D derivative or analogue"></PatentFamily><PatentFamily id="51638" number="WO-03106412" title="Epimerization of analogs of vitamin D"></PatentFamily><PatentFamily id="59741" number="WO-2004087170" title="Combination of a macrolide t-cell immunomodulator and a calciferol for the treatment of skin diseases or of inflammatory bowel disease"></PatentFamily><PatentFamily id="647754" number="EP-00749752" title="Use of specific RXR receptor ligands"></PatentFamily><PatentFamily id="655162" number="WO-2006138056" title="Pharmaceutical composition comprising a mahonia aquifolium extract for the treatment of psoriasis"></PatentFamily><PatentFamily id="663323" number="WO-2011076208" title="Calcipotriol monohydrate nanocrystals"></PatentFamily><PatentFamily id="701646" number="WO-2008110819" title="Polyaphron topical composition with vitamin D"></PatentFamily><PatentFamily id="715479" number="WO-00156981" title="Use of vitamin D-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin D3-derivatives"></PatentFamily><PatentFamily id="789695" number="WO-2009007785" title="Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses"></PatentFamily><PatentFamily id="790620" number="WO-2009098595" title="Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses"></PatentFamily><PatentFamily id="822079" number="WO-2010075537" title="Formulations comprising vitamin D or derivatives thereof"></PatentFamily><PatentFamily id="845219" number="WO-2005067405" title="Method for screening responsiveness to drugs effective in treatment or prevention of vitiligo and method for prognosis of vitiligo"></PatentFamily><PatentFamily id="847048" number="WO-2006120682" title="Compositions and methods for treating hyperproliferative epidermal diseases"></PatentFamily><PatentFamily id="847390" number="WO-2006129161" title="Vitamin formulation"></PatentFamily><PatentFamily id="878003" number="WO-2005105071" title="A topical composition containing a vitamin D derivative"></PatentFamily><PatentFamily id="945079" number="WO-2010039251" title="Stabilized composition for treating psoriasis"></PatentFamily><PatentFamily id="968646" number="WO-2012127037" title="Composition comprising lipid nanoparticles and a corticosteroid or vitamin D derivative"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>10</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>8</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>30</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>40</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>7</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Acrux Ltd" id="1003133"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Foamix Pharmaceuticals Ltd" id="1008035"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universität Osnabrück" id="1010901"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="School Foundation Eulji" id="1015382"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Avexxin AS" id="1020430"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="PLS-Design GmbH" id="1021453"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="DermiPsor Ltd" id="1024280"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Formosa Laboratories Inc" id="1025298"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Apollo Pharmaceutical, Inc" id="1025452"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Jingxin Pharmaceutical Co Ltd" id="1030336"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BrainScope Co Inc" id="1031655"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="College de France" id="1034577"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Association Pour La Recherche A L'Igbmc (ARI)" id="1037392"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kirin Holdings Co Ltd" id="1037687"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Huapont Life Sciences Co Ltd" id="1047813"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tianjin KingYork Group" id="1056725"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lipidor AB" id="1062277"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Haisco Pharmaceutical Group Co Ltd" id="1063506"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Zeyuan Pharmaceutical Co Ltd" id="1070621"></CompanyLink><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sino Biopharmaceutical Ltd" id="1073089"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Taiwan Union Chemical Co Ltd" id="1074619"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xi'an Libang Pharmaceutical Co Ltd" id="1084120"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Jingxin Biopharmaceutical Co Ltd" id="1084946"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tver State Medical Academy" id="1086607"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Allergan plc" id="1088700"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Perrigo Co plc" id="1091305"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xiamen Ants-Bro Technology Co Ltd" id="1093545"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China Three Gorges University" id="1096284"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Changsha Baishun Biotechnology Co Ltd" id="1110590"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Seelos Therapeutics Inc" id="1130356"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hpf Ip Holding Sa" id="1140874"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xiamen An Pu Dun Information Technology Co. Ltd" id="1144928"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chongqing Winbond Pharmaceutical Co. Ltd" id="1174583"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kunshan Puruikai Nanotechnology Co ltd" id="1179949"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guangzhou Nanfeng Biotechnology Co Ltd" id="1184248"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Angiogenesis Foundation" id="1189318"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Salk Institute for Biological Studies" id="14166"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="LEO Pharma A/S" id="17774"></CompanyLink><CountAsOwner>18</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>18</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nestle SA" id="18477"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hebrew University of Jerusalem" id="20586"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Université De Strasbourg" id="20609"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Pennsylvania" id="20658"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Sydney" id="20681"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Laboratorios Vinas SA" id="20745"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ben-Gurion University Of The Negev" id="22256"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Hamburg" id="25171"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pharmaceutical Research Institute" id="25181"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Tennessee" id="26292"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Panda Pharmaceuticals LLC" id="26477"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tecnimede-Sociedade Technico-Medicinal SA" id="27976"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Glenmark Pharmaceuticals Ltd" id="29326"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Astion Pharma A/S" id="30636"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>